Nelson Sewankambo K
ID: UNCST-2020-R014578
|
Evaluation of an Information Management and Communication System for Population-wide Point-of-Care Infant Sickle Cell Disease Screening (SIMCS)- A Cluster Randomized Trial
REFNo: HS6567ES
(ii) To evaluate the impact of the SCD SIMCS on access to screening and care and outcomes of children with SCD,
|
Jinja, Kakindu
Iganga,
Mayuge,
Kayunga,
|
Uganda |
2025-12-05 18:30:02 |
2028-12-05 |
60 Health centers |
Infants aged 4-6 months |
National Institutes of Health |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Bruce Kirenga J
ID: UNCST-2019-R001460
|
Safety, preliminary efficacy, and Pharmacokinetics of Herbal/Natural/ Traditional therapeutic products for the management of Diabetes Mellitus in Uganda.
REFNo: HS6530ES
Main Objective
1. To evaluate the safety, effectiveness and pharmacokinetics of 3 selected NDA- notified herbal/natural/traditional therapeutic products in Uganda, designated IMP1, IMP2, and IMP3.
2. To explore the experiences of innovators, researchers, implementers, and participants involved in this study on the innovation and scientific evaluation of natural therapeutics in Uganda.
Specific Objectives
1. To determine the efficacy of selected NDA-notified herbal/natural/traditional therapeutic products (IMP1, IMP2 and IMP3) used in the treatment of diabetes mellitus in adult patients in Uganda
2. 2. To assess the effect of the selected NDA-notified herbal/natural/traditional therapeutic products (IMP1, IMP2 and IMP3) on specific cardio-metabolic characteristics of adult patients with DM in Uganda.
3. To assess clinical and laboratory adverse events associated with selected NDA- notified herbal/natural/traditional therapeutic products, specifically IMP1, IMP2 and IMP3 in adult patients with DM in Uganda.
4. To investigate the pharmacokinetic profile(s) of NDA-notified herbal/natural/traditional therapeutic products (IMP1, IMP2 and IMP3) used in the management of DM.
5. To explore the experiences of innovators, researchers, implementers, and participants involved in this study on the innovation and scientific evaluation of herbal/natural/traditional therapeutics in Uganda.e the pharmacokinetic profile(s) of NDA-notified herbal/natural/traditional therapeutic products (IMP1, IMP2 and IMP3) used in the management of DM.
|
|
Uganda |
2025-12-01 14:19:22 |
2028-12-01 |
424 |
Objective 1- 4
Persons with a new or known diagnosis of diabetes mellitus
Objective 5
Personnel working in research programs, including: Investigators, Program managers, Clinical staff
Innovators of herbal/natural/ traditional therapeutic products purposed for diabetes mellitus management.
Objective 1-4
Adult (≥18 years) patients with recently diagnosed diabetes mellitus (diagnosis made in the preceding three months)
Objective 5
Individuals who have worked with the CONAT program as investigators, program manager, or clinical staff for at least six months.
Innovators of herbal/natural/ traditional products for diabetes mellitus whose product will be found during the survey.
|
Government of Uganda-STI-OP |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
Sarah Wilker
ID: UNCST-2025-R019791
|
One size fits all? Towards individual prediction of treatment success for posttraumatic stress disorder in post-conflict settings (TRAUMA-FIT)
REFNo: HS6712ES
Main Objective
1. to identify individual predictors of treatment response to two different treatments in survivors with PTSD in a post-conflict setting
Specific Objectives
1. Investigate whether NET is, on average, more effective than PM+ for the treatment of PTSD
2. Identify predictors of optimal response in the two conditions, and thereby identify predictors of treatment success in a trauma-focused versus present-focused treatment
3. Investigate the explanatory role of socio-ecological factors in PTSD treatment response
|
Gulu,
|
Germany |
2025-11-26 14:28:24 |
2028-11-26 |
660 |
(1) Adults of Age between 18 and 65; men and women, Acholi tribe (2) Survivor of trauma related to the LRA conflict or ongoing violence in the post-conflict setting; and (3) Probable diagnosis of PTSD according to DSM-5 (PSSI-5). |
German Research Foundation |
Medical and Health Sciences |
Clinical Trial |
Degree Award |
|
MALLON TUSUUBIRA
ID: UNCST-2025-R021850
|
SURVEY ON PARATUBERCULOSIS IN SLAUGHTERED GOATS AT KAMPALA CITY ABATTIOR
REFNo: A654ES
General objective
To establish the prevalence of Mycobacterium avium subsp. paratuberculosis infection in goats
Specific Objectives
i. To determine the prevalence of the gross and microscopic lesions associated with paratuberculosis in the ileocecal junction and associated lymph nodes of goats slaughtered at Kampala city abattoir
ii. To establish the prevalence of Mycobacterium avium sub species paratuberculosis in suspected cases using polymerase chain reaction (PCR)
|
Wakiso, Kampala
|
Uganda |
2025-11-21 14:36:09 |
2028-11-21 |
The sample size required will be calculated by using the formula of the estimation of prevalence in a population (Thrusfield et al., 2018). n = Z².p.(1-p)/d² Where: • n = sample size required • Z = Z-value (1.96 at a 95% confidence interval) • p = expected prevalence (According to standard epidemiologic practices 50% will be used since the prevalence is unknown). (Thrusfield, 2018; Dohoo et al,2009) • d = precision (5%) n = 1.96².0.5. (1-0.5)/0.05² = 384 |
The samples will be obtained from Kampala city Abattoir, a large goat slaughter house along the old Port Bell Road. The samples will be analysed in the histopathology research laboratory (CDL) and the pathology Laboratory, SVAR Makerere University. The study population will be goats that are brought to the abattoir for slaughter. The goats are from different parts of Uganda, with the majority coming from central and western Uganda. They will be offering a representative population to study the prevalence and incidence of paratuberculosis. The target population will be all the slaughtered goats at the abattoir during the study period. |
Self sponsored |
Agricultural Sciences |
Clinical Trial |
Degree Award |
|
Martin Origa Jobson Ariel
ID: UNCST-2022-R010809
|
Validation of cervical cancer screening methods in Uganda: The National Cancer Management and Capacity building Project in Uganda (CANCAP UG) experience.
REFNo: HS6635ES
To assess multiple screening methods: VIA, PAP smear, HPV, and colposcopy, plus or minus biopsy.,To evaluate the indicators of screening accuracy (sensitivity, specificity, positive predictive value, negative predictive value) of Visual Inspection with Acetic acid (VIA) test by comparing with the gold standard of disease status confirmed via histological results.,
|
Mbarara, cities
Mbarara, cities
Kampala, mulago
Kampala, kisenyi
|
Uganda |
2025-11-21 14:33:45 |
2028-11-21 |
4000 |
All women, 25 years old meeting the inclusion criteria and attending the screening clinic at CANCAP sites |
uganda cancer insitute |
Medical and Health Sciences |
Clinical Trial |
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|